BIOMAT Database Logo BIOMAT Database Logo

Detection of t(2;5)(p23;q35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis. 1996

M Beylot-Barry, and L Lamant, and B Vergier, and A de Muret, and S Fraitag, and B Delord, and P Dubus, and L Vaillant, and M Delaunay, and G MacGrogan, and C Beylot, and A de Mascarel, and G Delsol, and J P Merlio
Department of Pathology, CHU de Bordeaux et Université de Bordeaux II, France.

The t(2;5) generates a chimeric NPM-ALK transcript encoded by the nucleophosmin NPM gene fused to the anaplastic lymphoma kinase gene ALK. Using a reverse transcriptase nested polymerase chain reaction assay we have detected NPM-ALK transcripts within CD30+ primary cutaneous lymphoma and lymphomatoid papulosis (LP). The t(2;5) was identified in 4 out of 9 CD30+ anaplastic lymphomas and in 1 out of 4 CD30+ pleomorphic lymphomas. Moreover, the t(2;5) was detected in 3 out of 10 LPs. All NPM-ALK-positive lymphomas and 1 NPM-ALK-positive LP exhibited a clonal rearrangement of the T cell receptor gamma-chain gene. The t(2;5) was detected in 2 cases of LP without other evidence for a clonal lymphoid population. To identify cells carrying the t(2;5) translocation, we used immunohistochemistry to detect the ALK-encoded p80 protein and in situ hybridization for the specific detection of NPM-ALK transcripts. Both p80 protein and NPM-ALK transcripts were expressed by anaplastic or large CD30+ lymphoma cells with positive NPM-ALK amplification. The presence of t(2;5) in a subset of CD30+ cutaneous lymphoma and LP may indicate a common pathogenesis with a subset of anaplastic nodal lymphoma.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D002889 Chromosomes, Human, Pair 2 A specific pair of human chromosomes in group A (CHROMOSOMES, HUMAN, 1-3) of the human chromosome classification. Chromosome 2
D002895 Chromosomes, Human, Pair 5 One of the two pairs of human chromosomes in the group B class (CHROMOSOMES, HUMAN, 4-5). Chromosome 5
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M Beylot-Barry, and L Lamant, and B Vergier, and A de Muret, and S Fraitag, and B Delord, and P Dubus, and L Vaillant, and M Delaunay, and G MacGrogan, and C Beylot, and A de Mascarel, and G Delsol, and J P Merlio
Low frequency association of the t(2;5)(p23;q35) chromosomal translocation with CD30+ lymphomas from American and Asian patients. A reverse transcriptase-polymerase chain reaction study.
February 1995, The American journal of pathology,
M Beylot-Barry, and L Lamant, and B Vergier, and A de Muret, and S Fraitag, and B Delord, and P Dubus, and L Vaillant, and M Delaunay, and G MacGrogan, and C Beylot, and A de Mascarel, and G Delsol, and J P Merlio
Analysis of the t(2;5) (p23;q35) translocation in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease.
March 1998, Leukemia & lymphoma,
M Beylot-Barry, and L Lamant, and B Vergier, and A de Muret, and S Fraitag, and B Delord, and P Dubus, and L Vaillant, and M Delaunay, and G MacGrogan, and C Beylot, and A de Mascarel, and G Delsol, and J P Merlio
Detection of t(2;5)(p23;q35) in anaplastic large-cell lymphoma by long-range nested polymerase chain reaction assay.
January 2013, Methods in molecular biology (Clifton, N.J.),
M Beylot-Barry, and L Lamant, and B Vergier, and A de Muret, and S Fraitag, and B Delord, and P Dubus, and L Vaillant, and M Delaunay, and G MacGrogan, and C Beylot, and A de Mascarel, and G Delsol, and J P Merlio
Molecular detection of the (2;5) translocation of non-Hodgkin's lymphoma by reverse transcriptase-polymerase chain reaction.
June 1995, Blood,
M Beylot-Barry, and L Lamant, and B Vergier, and A de Muret, and S Fraitag, and B Delord, and P Dubus, and L Vaillant, and M Delaunay, and G MacGrogan, and C Beylot, and A de Mascarel, and G Delsol, and J P Merlio
Improved DNA-based polymerase chain reaction amplification of t(2;5)(p23;q35) breakpoints.
July 2000, International journal of hematology,
M Beylot-Barry, and L Lamant, and B Vergier, and A de Muret, and S Fraitag, and B Delord, and P Dubus, and L Vaillant, and M Delaunay, and G MacGrogan, and C Beylot, and A de Mascarel, and G Delsol, and J P Merlio
The use of fluorescent in situ hybridization for detection of the t(2;5)(p23;q35) translocation in anaplastic large-cell lymphoma.
January 1997, Annals of oncology : official journal of the European Society for Medical Oncology,
M Beylot-Barry, and L Lamant, and B Vergier, and A de Muret, and S Fraitag, and B Delord, and P Dubus, and L Vaillant, and M Delaunay, and G MacGrogan, and C Beylot, and A de Mascarel, and G Delsol, and J P Merlio
Three children with CD30 cutaneous anaplastic large cell lymphomas bearing the t(2;5)(p23;q35) translocation.
January 2004, Pediatric dermatology,
M Beylot-Barry, and L Lamant, and B Vergier, and A de Muret, and S Fraitag, and B Delord, and P Dubus, and L Vaillant, and M Delaunay, and G MacGrogan, and C Beylot, and A de Mascarel, and G Delsol, and J P Merlio
NPM-ALK Reverse Transcriptase-Polymerase Chain Reaction Analysis for Detection of the t(2;5) Translocation of Non-Hodgkin's Lymphoma.
January 1996, Methods in molecular medicine,
M Beylot-Barry, and L Lamant, and B Vergier, and A de Muret, and S Fraitag, and B Delord, and P Dubus, and L Vaillant, and M Delaunay, and G MacGrogan, and C Beylot, and A de Mascarel, and G Delsol, and J P Merlio
Solitary primary cutaneous CD30+ large cell lymphoma of natural killer cell phenotype bearing the t(2;5)(p23;q35) translocation and presenting in a child.
October 2000, The American Journal of dermatopathology,
M Beylot-Barry, and L Lamant, and B Vergier, and A de Muret, and S Fraitag, and B Delord, and P Dubus, and L Vaillant, and M Delaunay, and G MacGrogan, and C Beylot, and A de Mascarel, and G Delsol, and J P Merlio
High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining.
January 1996, Blood,
Copied contents to your clipboard!